Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits

The outbreak of the SARS-CoV-2 global pandemic heightened the pace of vaccine development with various vaccines being approved for human use in a span of 24 months. The SARS-CoV-2 trimeric spike (S) surface glycoprotein, which mediates viral entry by binding to ACE2, is a key target for vaccines and...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Kennedy, Martha M, Abolnik, Celia, Smith, Tanja, Motlou, Thopisang, Goosen, Kruger, Sepotokele, Kamogelo M, Roth, Robyn, du Preez, Ilse, Truyts, Alma, Stark, Hester C, Magwaza, Martin, Mahanjana, Osborn, Verschoor, Jan A., Moore, Penny L., Lemmer, Yolandy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968623/
https://www.ncbi.nlm.nih.gov/pubmed/36868876
http://dx.doi.org/10.1016/j.vaccine.2023.02.050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968623/
https://www.ncbi.nlm.nih.gov/pubmed/36868876
http://dx.doi.org/10.1016/j.vaccine.2023.02.050

Ejemplares similares